Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Sep 17, 2024 (2 years ago)

Atovaquone Oral Suspension

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Microbial Contamination of a Non-sterile Product: The product was found to be contaminated with Cohnella bacteria.

Cause type: Microbial contamination

Bacteria, mold, yeast or other microorganisms detected in the product. Contamination can occur from water systems, equipment or handling, and can cause infection. All microbial contamination recalls.

What was recalled

Atovaquone Oral Suspension, USP 750 mg/5 mL, 210 mL bottle, Rx only, Distributed by: Bionpharma Inc., Princeton, NJ 08540, NDC # 69452-252-87.

Affected NDC 69452-0252-87

Compare with the code on your package — it is the most precise check available.

Drug: Atovaquone

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Atovaquone
NDC 69452-0252
750 mg/5mL Suspension
Oral
Bionpharma Inc. Rx
Recalling firm
Bionpharma Inc.
NDC code
69452-252-87
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
Company announcement
Sep 17, 2024 · FDA notice with lot numbers
FDA recall number
D-0012-2025 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Atovaquone recalls

See all
Class I · High risk

Atovaquone Oral Suspension USP

Microbial Contamination of Non-Sterile Product: Objectionable organism, identified as Bacillus cereus, found in product during testing of repackaged product.

Ongoing Microbial contamination Camber Pharmaceuticals Inc. NDC 31722-629-21 D-0567-2023
Class II · Moderate risk

All Malarone

Lack of Processing Controls

Terminated cGMP deviation Reliable Rexall-A Compounding Pharmacy D-1136-2016
Class II · Moderate risk

Atovaquone active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-528-2015

Other recalls by Bionpharma Inc.

All 2024 recalls
Class II · Moderate risk

Clobazam Oral Suspension

Microbial Contamination of Non-Sterile Products: Out-of-specification results for Microbial Enumeration Tests USP <61> was observed.

Terminated Microbial contamination Bionpharma Inc. NDC 69452-116-45 D-1519-2019